SEC Comment Letter 0000000000-23-007818 to PepperLime Health Acquisition Corp (CIK 0001873324)
PepperLime Health Acquisition Corp (CIK 0001873324)
Date: July 21, 2023 · CIK: 0001873324 · Accession: 0000000000-23-007818
AI Filing Summary & Sentiment
File numbers found in text: 001-40915
Letter
United States securities and exchange commission logo July 21, 2023 Ramzi Haidamus Chief Executive Officer PepperLime Health Acquisition Corporation 548 Market Street, Suite 97425 San Francisco, CA 94104 Re:PepperLime Health Acquisition Corporation Preliminary Proxy Statement on Schedule 14A Filed July 13, 2023 File No. 001-40915 Dear Ramzi Haidamus: We have reviewed your filing and have the following comment. In our comment, we may ask you to provide us with information so we may better understand your disclosure. Please respond to this comment within ten business days by providing the requested information or advise us as soon as possible when you will respond. If you do not believe our comment applies to your facts and circumstances, please tell us why in your response. After reviewing your response to this comment, we may have additional comments. Preliminary Proxy Statement on Schedule 14A filed July 13, 2023 Risk Factors The Committee on Foreign Investment in the United States ("CFIUS")..., page 4 1.We refer to your letter, dated January 25, 2023, submitted in response to the review of your Annual Report on Form 10-K for the fiscal year ended December 31, 2021, where you confirmed that your sponsor has substantial ties with non-U.S. persons and that certain of your board members are non-U.S. persons, and where you had proposed risk disclosure. To the extent that such proposed disclosure continues to be applicable, please revise your risk factor disclosure to include information provided in such proposed disclosure, including the fact that members of your Board are non-U.S. persons, so that investors have the necessary context to assess the risk you disclose. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
FirstName LastNameRamzi Haidamus Comapany NamePepperLime Health Acquisition Corporation July 21, 2023 Page 2 FirstName LastName Ramzi Haidamus PepperLime Health Acquisition Corporation July 21, 2023 Page 2 Please contact Ronald (Ron) E. Alper at 202-551-3329 or Dorrie Yale at 202-551-8776 with any questions. Sincerely, Division of Corporation Finance Office of Real Estate & Construction cc: Giovanni Caruso
Show Raw Text
United States securities and exchange commission logo
July 21, 2023
Ramzi Haidamus
Chief Executive Officer
PepperLime Health Acquisition Corporation
548 Market Street, Suite 97425
San Francisco, CA 94104
Re:PepperLime Health Acquisition Corporation
Preliminary Proxy Statement on Schedule 14A
Filed July 13, 2023
File No. 001-40915
Dear Ramzi Haidamus:
We have reviewed your filing and have the following comment. In our comment, we
may ask you to provide us with information so we may better understand your disclosure.
Please respond to this comment within ten business days by providing the requested
information or advise us as soon as possible when you will respond. If you do not believe our
comment applies to your facts and circumstances, please tell us why in your response.
After reviewing your response to this comment, we may have additional comments.
Preliminary Proxy Statement on Schedule 14A filed July 13, 2023
Risk Factors
The Committee on Foreign Investment in the United States ("CFIUS")..., page 4
1.We refer to your letter, dated January 25, 2023, submitted in response to the review of
your Annual Report on Form 10-K for the fiscal year ended December 31, 2021, where
you confirmed that your sponsor has substantial ties with non-U.S. persons and that
certain of your board members are non-U.S. persons, and where you had proposed risk
disclosure. To the extent that such proposed disclosure continues to be applicable, please
revise your risk factor disclosure to include information provided in such proposed
disclosure, including the fact that members of your Board are non-U.S. persons, so that
investors have the necessary context to assess the risk you disclose.
We remind you that the company and its management are responsible for the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action or absence of
action by the staff.
FirstName LastNameRamzi Haidamus
Comapany NamePepperLime Health Acquisition Corporation
July 21, 2023 Page 2
FirstName LastName
Ramzi Haidamus
PepperLime Health Acquisition Corporation
July 21, 2023
Page 2
Please contact Ronald (Ron) E. Alper at 202-551-3329 or Dorrie Yale at 202-551-8776
with any questions.
Sincerely,
Division of Corporation Finance
Office of Real Estate & Construction
cc: Giovanni Caruso